384 Participants Needed

Our Practice Advisory for Physician Workflow

KC
Overseen ByKatelyn Clinical Research Coordinator
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Los Angeles
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to help doctors make better choices when ordering certain lab tests, specifically Hemoglobin A1c (used to monitor blood sugar) and Thyroid-Stimulating Hormone (TSH) tests. The goal is to reduce unnecessary repeat tests within 30 days, which often do not provide new information. By providing doctors with reminders through their electronic health records using the Practice Advisory (OPA), the study seeks to improve test utilization and enhance patient care. The trial is ideal for patients at UCLA Health who have had recent A1c or TSH tests in the last month. As an unphased trial, it offers patients the opportunity to contribute to optimizing healthcare practices and improving patient care.

Do I have to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It focuses on testing practices rather than medication use.

What prior data suggests that this protocol is safe for provider decision-making?

Research shows that the Our Practice Advisory (OPA) helps doctors make better decisions when ordering tests like Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH). Although specific safety data for OPA is unavailable, it is important to note that it is not a drug or medical procedure. Instead, it supports decision-making and does not directly affect the body, so there are no typical side effects or safety concerns like those associated with medications.

OPA aims to reduce unnecessary repeat testing, saving time and resources without compromising the quality of patient care. No evidence suggests negative effects from using this advisory tool, making it safe for use in medical settings. Therefore, participating in this type of study involves little to no risk to health.12345

Why are researchers excited about this trial?

Researchers are excited about the Our Practice Advisory (OPA) because it offers a new approach to reducing unnecessary medical testing. Unlike current standard practices that often lead to repeated tests, OPA provides real-time alerts through the electronic health record (EHR) system, prompting healthcare providers to reconsider ordering Hemoglobin A1c and Thyroid-Stimulating Hormone tests if they have been requested within the past 30 days. This proactive strategy aligns with evidence-based guidelines, aiming to optimize testing efficiency and enhance patient care. By minimizing redundant tests, OPA has the potential to streamline physician workflow and reduce healthcare costs, making it a promising innovation in medical practice management.

What evidence suggests that this advisory is effective for reducing unnecessary A1c and TSH testing?

Research shows that the Our Practice Advisory (OPA), which participants in this trial may receive, reduces unnecessary repeat tests by following evidence-based guidelines. Studies have found that when doctors receive these alerts, they reconsider ordering tests like Hemoglobin A1c and Thyroid-Stimulating Hormone if conducted in the past 30 days. This approach can lead to better resource use and improve patient care by avoiding repeated tests. The alerts aim to help doctors make more efficient decisions, ultimately enhancing patient outcomes without overburdening the healthcare system.678910

Are You a Good Fit for This Trial?

This trial is for healthcare providers who order Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) tests. It aims to improve their decision-making by reducing unnecessary repeat testing within a short period.

Inclusion Criteria

I am 18 years old or older.
Hemoglobin A1c (A1c) and Thyroid-Stimulating Hormone (TSH) ordered, AND this lab was ordered and resulted within the prior 30 days
Inpatient or observation stays within UCLA Health System hospitals

Exclusion Criteria

Have an A1c or TSH ordered and do not have a result for one of these labs in the prior 30 days

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Providers receive or do not receive the Our Practice Advisory (OPA) when ordering A1c and TSH tests within 30 days of prior results

6 months

Follow-up

Participants are monitored for changes in test ordering behavior and outcomes

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Our Practice Advisory (OPA)
Trial Overview The study evaluates the effectiveness of Our Practice Advisory (OPA), which are alerts that guide providers towards evidence-based practices, particularly in ordering A1c and TSH tests.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: OPA Intervention GroupExperimental Treatment1 Intervention
Group II: Control GroupActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials
1,594
Recruited
10,430,000+

Citations

Our Practice Advisory for Physician WorkflowIt aims to improve their decision-making by reducing unnecessary repeat testing within a short period. ... Trial Overview The study evaluates the effectiveness of ...
Evaluating a Our Practice Advisory (OPA) to Optimize ...The OPA will prompt providers to reconsider the test if it was ordered within the previous 30 days, aligning with evidence-based guidelines to ...
NOVEL BEST PRACTICE ADVISORIES TO REDUCE ...Best Practice Advisory (BPA) pop-ups and alarms can potentially be used to curb over-testing, but they can also burden providers in a healthcare ...
Optimizing Best Practice Advisory alerts in electronic ...Alerts can be optimized through a multipronged strategy. Our study aims to describe these strategies adopted and evaluate the resultant BPA alert optimization ...
Real-World Results from IntelliSep at OLOL... Our Lady of the Lake Regional Medical Center enhanced early recognition and treatment by developing a protocol using Epic's Our Practice Advisory (OPA) alerts.
Table of Surrogate Endpoints That Were the Basis of Drug ...This surrogate endpoint table includes surrogate endpoints that sponsors have used as primary efficacy clinical trial endpoints for approval of new drug ...
Core Set of Adult's Health Care Quality Measures for ...For the Adult Core Set, the measure is reported for beneficiaries age 20 and older. i The Hemoglobin A1c Control for Patients With Diabetes (HBD-AD) measure ...
Recommendations for Improving the Core Sets of Health ...NCI data is used to measure the Missouri Quality Outcomes. The ... The Hemoglobin A1C (HbA1c) Testing. (HA1C-AD) measure is an important ...
Physician-Related Services/Health Care Professional ...• CPT® code 83037 [hemoglobin glycosylated (A1C)] does not require PA when performed in a physician's office; however, it can be billed only ...
MOLINA HEALTHCARE OF CALIFORNIAThe reduction in risk of the complications of diabetes is directly correlated with an A1C level of <7%. Perform A1C tests at least two times a year for patients ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security